FindTrial
Sign In

DHAP

DRUG7 trials

Sponsors

Jonsson Comprehensive Cancer Center, University of Magdeburg, MedImmune LLC, University of Cologne, Kyowa Kirin, Inc.

Conditions

Adult T-cell Leukemia-LymphomaDiffuse Large B-Cell LymphomaHodgkin LymphomaLymphomaMalaria Asymptomatic ParasitaemiaMalaria FalciparumMalaria InfectionMalaria Transmission

Phase 1

Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
NCT00384553
University of MagdeburgNon-Hodgkin's Lymphoma
Start: 2004-06-30End: 2010-06-30Target: 30Updated: 2006-10-06
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
CompletedNCT01453504
University of CologneHodgkin Lymphoma
Start: 2012-08-31End: 2019-03-31Updated: 2019-11-08
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
NCT02280993
Marjolein SpieringHodgkin Lymphoma, Refractory, Relapse
Start: 2014-05-31End: 2020-05-31Target: 72Updated: 2018-03-13

Phase 2

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
CompletedNCT00003143
Jonsson Comprehensive Cancer CenterLymphoma
Start: 1997-11-30Updated: 2012-10-04
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
CompletedNCT01453205
MedImmune LLCDiffuse Large B-Cell Lymphoma
Start: 2012-02-27End: 2016-07-11Updated: 2018-03-12
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
CompletedNCT01626664
Kyowa Kirin, Inc.Adult T-cell Leukemia-Lymphoma
Start: 2012-06-30End: 2018-02-28Updated: 2024-04-25

Unknown Phase

Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana
RecruitingNCT07389057
Noguchi Memorial Institute for Medical ResearchMalaria Asymptomatic Parasitaemia, Malaria Falciparum, Malaria Infection +1
Start: 2023-11-01End: 2026-11-30Target: 9000Updated: 2026-02-05

Related Papers

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
Hematological Oncology2025-06-281 citations
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
Blood Advances2023-09-1816 citations
Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma
Blood2022-11-151 citations
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.
2022-10-1415 citations
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Haematologica2020-04-0992 citations
PS1240 EVEROLIMUS WITH DHAP (DEXAMETHASONE, HIGH‐DOSE ARAC, CISPLATINUM) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A RANDOMIZED, PLACEBO‐CONTROLLED PHASE I/II TRIAL (HD‐R3I)
HemaSphere2019-06-01
Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)
Blood2018-11-292 citations
Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma.
2018-05-1139 citations
A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL).
Journal of Clinical Oncology2016-05-2011 citations
Differences between Japan and rest of world (ROW) in disease presentation and outcome of previously treated adult t-cell leukemia-lymphoma (ATL) using therapy with a monoclonal antibody to CCR4, mogamulizumab (moga).
Journal of Clinical Oncology2016-05-20
Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator’s choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).
Journal of Clinical Oncology2014-05-201 citations